The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.
Category: Environment
Biotech Investors Are Tuning Out the MAHA Chaos
The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.
How one Oregon city has raised a billion dollars for climate change
The Portland Clean Energy Fund has raised a billion dollars for climate change action via a…
Zambia Helped Chinese Miner Cover Up Pollution Disaster, House Committee Finds
Toxic waste inundated homes and fields in a spill over a year ago. Zambia is relying…
Ligand Pharmaceuticals said it has reached a deal to acquire Xoma Royalty, a company that invests in a range of biotech firms, for around $740 million
Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect…
Eli Lilly Strikes Deal for Cancer Biotech
The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.
Eli Lilly Strikes Deal for Cancer Biotech
The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.
Heard on the Street: Pharmaceutical companies are opting to make smaller biotech acquisitions. That’s great news for biotech stocks.
Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of…
GFL Environmental Expands Into Energy Sector With $4.6 Billion Secure Waste Acquisition
The deal pushes one of North America’s largest waste-disposal companies into Canada’s oilpatch.
Big Pharma Is Thinking Small on Deals. That’s a Boon for Biotech.
Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of…